Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 3Unknown 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Sarcoma 1

Conditions

Vomiting 5Neoplasms 3Nausea 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Testicular Neoplasms 1Sarcoma 1Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79Bevacizumab 75pembrolizumab 74Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms × fosaprepitant × Clear all
NCT03578081 2025-04-06

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
690 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT04508400 2024-01-09

Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients

Sun Yat-sen University

Phase 2 Completed
108 enrolled
Tumor-Agnostic

Neoplasms

NCT01490060 2016-04-11

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

M.D. Anderson Cancer Center

Phase NA Completed
47 enrolled 6 charts
Sarcoma

Nausea, Neoplasms, Sarcoma, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡